Cumulative Index 1988

Volume 8

April THERAPEUTIC ADVANCES IN CLINICAL IMMUNOLOGY, pages 1–182
August NEUROIMMUNE DISORDERS, pages 183–348
December GUT AND INTESTINAL IMMUNOLOGY, pages 349–584

Note: Page numbers of issues and articles are in **boldface** type.

Acetylcholine receptor, in myasthenia gravis, as autoantigen, 278–280
  autoantibodies against, 278–282
  function of, 277–278
  structure of, 277–278
Adrenocorticotrophic hormone, lymphocyte effects, 188–190
Age, and clinical immunology laboratory, 114–116
AIDS (acquired immunodeficiency syndrome), **451–467**
  bacterial infections, 457
  CD3-positive cytotoxic cells, 142
  clinical aspects and biological therapies, **93–109**
    future prospects, 104–105
    HIV infection, 100–102
    host immune response to HIV, 98–100
    immunoactive substances, clinical trials, 103–104
    immunoactive therapy, 102–103
    pathogenesis, 93–98
  enteric bacteremias, 462–464
    Campylobacter, 463
    liver disease, 463–464
    Salmonella, 462
    Shigella, 462
  fungal infections, 452–454
  intestinal parasites, 455–457
  mucosal immune system, 451–452
  viral infections, 457–462
    cytomegalovirus, 457–459
    herpes simplex virus, 459–460
    idiopathic diarrhea, 461–462
    Kaposi's sarcoma, 460–461
    lymphoma, 461
    See also *Antiretroviral therapy.*
Allergy, extraintestinal implications, 474–475
  food, 470–471
  and hypersensitivity, 469–470
  mast cells and eosinophils in, 479–480
  See also *Milk and food allergies in children.*
Alpha chains, IgA molecules, 350–352
Amyloidosis, with neuropathy, 302, 304–305
Amyotrophic lateral sclerosis, **331–341**
  autoimmunity, 332–336
    neural-specific, 333–336
  immunogenetic factors, 332–333
  monoclonal gammopathy, 337–338
  nonspecific immunity, 333
  paraneoplastic, 336–337
  symptoms, 331
Anemia, autoimmune hemolytic, IGIV treatment, 43
Animals, murine models of IL-2 toxin, 75–77
Ankylosing spondylitis, 562–563
Antibodies, anti-IL-2 receptor, 70–71
  in transplantation, 71
  B cells, immunoglobulin deficiency, 138–139
    intravenous immunoglobulin, 139
    polyclonal B cell activation, 137–138
  heteroconjugate, and interleukin-2 activated cells, 126–128
  humoral, in graft-versus-host disease, 552
  to IgA, intravenous immunoglobulin injections, 23–24
  OKT3 monoclonal, 69–70
  peptide vaccines, 174–177

Antigen-presenting cells, in immune response to virus, 224
Antigens, dietary, anti-idiotypes, 444–445
immune-associated, in graft-versus-host disease, 551
macromolecular absorption, in selective IgA deficiency, 441–442
Antipilus immunity, 401–402
Antiretroviral therapy, **79–92**
AZT (Retrovir), 89–90
cell binding and entry, 81–84
dideoxynucleosides, 86–89
HIV as retrovirus, 80–81
integration, latency, and reactivation, 84–85
protein production and assembly, 85–86
Antitoxin immunity, 402
Arginine-vasopressin, leukocyte effects of, 187
Arteritis, in SLE, cerebrovascular accident and, 318
neuropathology, 321
Arthritis, IGIV treatment, 45
stress effects, 117
and inflammatory bowel disease, 561–562
and intestinal bypass procedures, 561
neuromediators role in, 194
rheumatoid, intestinal manifestations, 566–567
pathogenesis, 563–564
Arthropathies, reactive, 559–560
seronegative, 562
Aseptic meningitis, in SLE, 319
Asthma, neuromediator role, 194–195
Ataxia, in SLE, 318
Autoantibodies, human Leu-1 B, homologous B-cells, **1–15**
Autoimmunity, amyotrophic lateral sclerosis and, 332–336
in graft-versus-host disease, 552–553
hypersensitivity, 471
nervous system involvement, **213–221**
in encephalomyelitis, 240, 243–245
immune response genes, 213–214, 216–217
immunotherapy, 217–220
in myasthenia gravis, 214–216
Autonomic nervous system function, in Guillain-Barré syndrome, 257, 267
Azathioprine, in myasthenia gravis, 285
meningitis induced by, 319
AZT (Retrovir), antiretroviral therapy, 89–90

B cells, and antibodies, 137–139
immunoglobulin deficiency, 138–139
intravenous immunoglobulin, 139
polyclonal B cell activation, 137–138
HLA antigen recognition by, 203
homologous, autoantibody secretion from human Leu-1 B, **1–15**
IgA differentiation, 161–166
cellular and molecular events, 161–162
lymphokines, 162–163
IgE differentiation pathway, 145–147
normal maturation, 423–424
Bacterial and parasitic infections, in AIDS, 457
intestinal immunity, **391–421**
Cryptosporidia, 410–411
Entamoeba histolytica, 413–415
Giardia species, 409–410
mucosal adherence, and enterotoxin production, 397–402
mucosal invasion, proliferaton in epithelial cells, 402–405
proliferation in lamina propria and mesenteric lymph nodes, 405–408
and systemic infection, 408–409
schistosomiasis, 411–413
IGIV treatment, 30–34
in malignancies, 34
neonatal, 32–33
in older infants and children, 33–34
and T-cell hybridomas, 141
Basophils, neuromediator effects, in immediate hypersensitivity, 186
Behçet's disease, 567–568
Biopsy, intestinal, in food allergies, 499
Bombesin, leukocyte effects, 187
Brain, infection of. See *Encephalitis; Encephalomyelitis.*
low HLA expression in, 227–228
progressive multifocal leukoencephalopathy, 232–233
Bullous pemphigoid, IGIV treatment, 45
neuromediators in, 195

C-3 proactivator, in Guillain-Barré syndrome, 259–260
C-reactive protein, in Guillain-Barré syndrome, 259–260
Calcitonin gene-related peptide, in immediate hypersensitivity, 184–186
Campylobacter infections, in AIDS, 463
before Guillain-Barré syndrome, 255
Campylobacter jejuni, 405–406
Cancer, paraneoplastic syndromes. See *Paraneoplastic syndromes.*
tumor-infiltrating lymphocytes and interleukin-2 treatment, 124–126
4–Carboxy-L-glutamic acid, 187
Carcinoma, neuromediators in, 195
CD2 (erythrocyte receptor), LFA-3 binding region, 59–61
T-cell activation, 52–59
CD23, and Fc epsilon receptors, 150–151

CD43 (sialophorin), 61–64
Celiac disease, **505–520**
clinical features, 506–508
associated diseases, 506
complications, 507–508
diagnosis, 506–507
treatment, 508
environmental factors, 509–512
dietary grans, 509–511
families and twins, 512
HLA and non-HLA markers, 513–515
humoral and cell-mediated immunity, 515–517
pathogenesis, 508–509
pathology, 505–506
Cell-mediated immunity, in celiac disease, 516–517
in viral infections, 227, 229
See *Lymphocyte populations, and cell-mediated immunity.*
Central nervous system, disorders of, and viruses, **239–249**
See also *Brain; Spinal cord.*
Cerebellar degeneration, subacute, with neoplastic disease, 296–298
Cerebrovascular accident, in SLE, 318
Children. See *Milk and food allergies in children.*
Cholera toxin immunity, 399–400
Chorea, in SLE, 318
Clinical immunology, AIDS, clinical and biological therapies, **93–109**
antiretroviral therapy, **79–92**
autoantibody secretion from human Leu-1 B, **1–15**
hypersensitivity, immediate, **145–155**
immunology of infection, **137–144**
intravenous immunoglobulin treatment, bacterial and viral infections, **29–38**
immunodeficiency primary diseases, **17–28**
in immunoregulatory disorders and in newborn period, **39–50**
lymphokines, **121–135**
T-cell activation, **51–67**
tumor immunology, **157–160**
vaccine development, **169–178**
Clinical Immunology Society, Second Annual Meeting, 117–118
Cold agglutinins, in Guillain-Barré syndrome, 260
Connective tissue diseases, **559–571**
ankylosing spondylitis, 562–563
arthritis, and inflammatory bowel disease, 561–562
and intestinal bypass procedures, 561
rheumatoid, pathogenesis of, 563–564
arthropathies, seronegative, 562
intestinal manifestations, 565–569
Behçet's disease, 567–568
dermatomyositis, 568–569
periarteritis nodosum, 565–566
rheumatoid arthritis, 566–567
scleroderma, 568
Sjögrens syndrome, 567
systemic lupus erythematosus, 565
reactive arthropathies, 559–560
Reiter's syndrome, 560–561
Whipple's disease, 562
Corticosteroids, in Guillain-Barré syndrome, 268–269
in SLE, 325–326
psychosis from, 324
Cranial neuropathy, in SLE, 317–318
Crohn's disease, 116
Cryptosporidia, 410–411
infections in AIDS, 455–456
Cyclophosphamide, and IL-2, for melanoma, 121–124
in myasthenia gravis, 285
in SLE, 326
Cytokines, in gastrointestinal immune system function, 379–382
in graft-versus-host disease, 553
Cytomegalovirus, 34–35
preceding Guillain-Barré syndrome, 153–154
infections in AIDS, 457–459
Cytotoxicity, antibody-dependent, in food allergies, 493
CD3-positive cells, in AIDS, 142
interleukin-2–activated cells, 126–128
of intestinal lymphocytes, 383–388
antibody-dependent, 384–386
non–antigen-specific, natural killer and lymphokine-activated killer cells, 384
intraepithelial lymphocytes, 387–388
lymphokine-activated killer cells, 131–133
T-cells, 386–387
and Epstein-Barr virus, 143
in measles, 230–232
in viral infections, 226–228

Demyelination, delayed hypersensitivity, 233–234
in Guillain-Barré syndrome, 257–261
in post-infectious encephalomyelitis, 243–245
Dermatomyositis, 568–569
Diabetes, IGIV treatment, 45
stress effects, 117
insulin-dependent, and HLA antigen, 204–205
Diarrhea, idiopathic, in AIDS, 461–462
Dideoxynucleosides, 86–89
Diphtheria toxin, 73
Drug action mechanisms, in inflammatory bowel disease, 536–537

Eaton-Lambert syndrome, 307–309
Echovirus, 35–36
Electromyography, in myasthenia gravis, 283–284
Electron microscopy, of acute graft-versus-host disease, 551
Encephalitis, herpes simplex, 229–230
  limbic, with neoplastic disease, 299–300
  subacute sclerosing, 230–232
Encephalomyelitis, after rabies vaccination, 239–242
  experimental allergic, 239–240
    HLA antigens, 205
    immunotherapy, 218–220
    multiple genetic influences, 208–209
  post-infectious, 239–240, 242–245
Endorphins, leukocyte effects, 187
  lymphocyte effects, 188–190
Endotoxin, and T cells and monocytes, 142–143
Entamoeba histolytica, 413–415
Enterotoxin production, 397–402
Environmental factors, in celiac disease, 509–512
Eosinophils. See *Hypersensitivity, gastrointestinal.*
Epilepsy, childhood, IGIV treatment, 45
Epithelial cells, IgA transport through, 354–357
Epstein-Barr virus infections, and Guillain-Barré syndrome, 254
Erythrocyte receptor (CD2), LFA-3 binding region, 59–61
  T-cell activation, 52–59
Escherichia coli, enteroinvasive, 405
  enterotoxigenic, 400–402
Esophagus, lesions in graft-versus-host disease, 548–549
Experimental allergic encephalomyelitis, 239–240
  HLA antigens, 205
  immunotherapy, 218–220
  multiple genetic influences, 208–209

Fatigue syndrome, post-infection, 139
Fc epsilon receptors, 147–152
  CD23 molecule, 250–252
  IgE regulation and production, 148–150
  natural killer cells, 149
Food allergy, 470–471
  See also *Milk and food allergies in children.*
Fungal infections, gastrointestinal, in AIDS, 452–454

Gammopathy, monoclonal, amyotrophic lateral sclerosis, 337–338
  neuropathy with, 302–306
Gastrin-releasing peptide, leukocyte effects, 187
Gastroenteritis, eosinophilic, 471–472
Gastrointestinal tract, in food allergies, 495–496
  See also *Gut and intestinal immunology.*
Genetics, of celiac disease, 512–515
  immune reactivity. See *Immunogenetics.*
Giardia species, 409–410
Glial-growth promoting factor, 191–192
Graft-versus-host disease of intestine and liver, **543–557**
  acute, 544–548
    clinical presentation, 545–547
    patients at risk, 544–545
    prevention and treatment, 547–548
  chronic, 548–550
    clinical presentation, 548–550
    patients at risk, 548
    patients at risk, 548
    prevention and treatment, 550
  immunopathogenesis, 550–553
    electron microscopy, 551
    epithelial expression of immune-associated antigen, 551
    immunodysregulation and autoimmunity, 552–553
    intestinal microflora and latent viruses, 552
    staining of tissue lymphoid cells, 550–551
Graft-versus-leukemia reactions, 159–160
Grains, dietary, in celiac disease, 509–511
Growth factor, for immature T cells, 133–135
Guillain-Barré syndrome, **251–275**
  antecedent events, 252
  blood studies, 259–260
  Campylobacter infection preceding, 255
  clinical features, 255–257
  cytomegalovirus infection preceding, 253–254
  electrodiagnostic studies, 259
  Epstein-Barr virus infection preceding, 254
  experimental allergic neuritis and, 252
  herpesvirus infection preceding, 253–255
  history of, 251–252
  human immunodeficiency virus and, 256
  humoral factors, 261–267
  infectious disease preceding, 252–255
  infectious mononucleosis preceding, 254
  mycoplasmal infection preceding, 254
  pathology, 257–259
  tissue injury mechanisms, 260–261
  treatment, 269–271
Gut and intestinal immunology, AIDS (acquired immunodeficiency syndrome), **451–467**
  bacteria, 457

enteric bacteremias, 462–464
fungal infections, 452–454
intestinal parasites, 455–457
mucosal immune system, 451–452
viruses, 457–462
bacterial and parasitic infections, **391–421**
Cryptosporidia, 410–411
Entamoeba histolytica, 413–415
Giardia species, 409–410
mucosal adherence and enterotoxin production, 397–402
mucosal invasion, proliferation in epithelial cells, 402–405
proliferation in lamina propria and mesenteric lymph nodes, 405–408
and systemic infection, 408–409
schistosomiasis, 411–413
celiac disease, **505–520**
clinical features, 506–508
environmental factors, 509–512
genetic factors, 512–515
humoral and cell-mediated immunity, 515–517
pathogenesis, 508–509
pathology, 505–506
connective tissue diseases, **559–571**
ankylosing spondylitis, 562–563
arthritis, and inflammatory bowel disease, 561–562
and intestinal bypass procedures, 561
arthropathies, reactive, 559–560
seronegative, 562
intestinal manifestations, 565–569
pathogenesis of rheumatoid arthritis, 563–564
Reiter's syndrome, 560–561
Whipple's disease, 562
graft-versus-host disease of intestine and liver, **543–557**
acute GVHD in humans, 544–548
chronic GVHD in humans, 548–550
immunopathogenesis, 550–553
hypersensitivity, mast cells and eosinophils, **469–483**
allergy, 469–470
eosinophils, 478–479
extraintestinal implications of allergy, 474–475
in gut allergy, 479–480
initiation of sensitivity, 472–474
mast cells, 477–478
mechanisms of, 475–476
problems and challenges, 480–482
spectrum of, 470–472
IgA system, **349–368**
polymeric IgA and molecules, assembly and transport, 354–357
selective deficiency, **435–449**
gastrointestinal diseases, 437–439
immunologic findings, 439–440
macromolecular antigen absorption, 441–445
nonimmunologic mucosal abnormalities, 440–441
origin, migration, and homing of, 358–361
structural aspects, 349–354
alpha chains, 350–352
J chain, 352–353
secretory component, 353–354
T-cell regulation, 361–365
tissue distribution, 361
immunodeficiency, common variable, **423–434**
B cells, normal maturation, 423–424
clinical presentation, 425
intestinal manifestations, 426–432
laboratory evaluation, 425–426
therapy, 432
inflammatory bowel disease, **521–542**
cell-mediated, antigen-specific memory events, 527–531
immunopharmacology and mechanisms of drug actions, 536–537
inflammatory and nonspecific effector mechanisms, 532–535
initiating events and activation of immune system, 523–527
lymphocytes, and cell-mediated immunity, **369–389**
cytokines, role of, 379–382
classification of subpopulations, 382
interferon-gamma, 381
interleukin-1, 379
interleukin-2, 378–379
interleukin-3, 380
interleukin-4, 380
interleukin-5, 380
interleukin-6, 380–381
lymphotoxin, 381
cytotoxic function, 383–388
antibody-dependent, 384–386
cytolytic cells, 388
intraepithelial lymphocytes, 387–388
non–antigen-specific, 384
T-cells, 386–387
immunoregulatory function of T cells, 374–377
lymphoid compartments of intestinal immune system, 370
neuroendocrine factors, 388
phenotypic characteristics, 370–374
intraepithelial lymphocytes, 371–373
lamina propria T-cell subpopulations, 371
markers of lymphocyte activation, 373–374
T-cell activation in lamina propria, 377–379
CD4 T cells, 378–379

Gut and intestinal immunology *(Continued)*
lymphocytes, T-cell antigen-receptor-triggered function, 382–383
milk allergies and other food allergies in children, **485–504**
clinical manifestations, 495–497
definition, 485–486
diagnosis, 497–499
incidence, 486
mucosal barrier, 486–491
pathogenesis, 491–495
therapy, 499–500

Headache, in SLE, 319–320
Hemophilia, IGIV treatment, 45
Hemorrhage, intracranial, in SLE, 318
Herpesvirus infections, 35
in AIDS, 459–460
before Guillain-Barré syndrome, 253–255
of nervous system, 228–230
Histamine-releasing factor, 152–155
cytokine-induced release of, 154
inflammation in late phase reactions, 153
urticaria, chronic, 153–154
Histocompatibility complex, in neurologic disease, 204–205
genetic considerations, 202–203
immune response genes, 213–214
HLA, antigens, immune response genes, 213–214
neurologic disease and, 204–205
T-cell recognition of, 203
complex, genetic considerations, 202–203
low expression of in nervous tissue, 227–228
and non-HLA markers, in celiac disease, 513–515
HNK-1/L_2 epitope, in IgM monoclonal gammopathy, 306
Human immunodeficiency virus (HIV), antiretroviral therapy, 80–81
clinical manifestations of infection, 100–102
and Guillain-Barré syndrome, 256
host immune response, 98–100
and neurologic disease, 234–235
Hypersensitivity, delayed type, targeting of chimeric interleukin-2–toxin to receptor, 129–130
in viral infection, 226–227
Theiler's murine encephalomyelitis virus and, 233–234
in food allergies, immediate-type, 491–493
immune complex-mediated, 493–494
cell-mediated, 494–495
gastrointestinal, **469–483**
allergy, 469–470
mast cells and eosinophils in, 479–480
eosinophils, 478–480
extraintestinal implications, 474–475
initiation of sensitivity, 472–474
mast cells, 477–478, 479–480
mechanisms of, 475–477
problems and challenges, 480–482
spectrum of, 470–472
autoimmune, 471
eosinophilic gastroenteritis, 471–472
food allergy, 470–471
infectious agents, 471
immediate, **145–155**
Fc epsilon receptors in isotype regulation, 147–152
IgE-committed B cells, 145–147
mononuclear cell derived histamine releasing factor, 152–155
neuromediation of, 184–186, 194–195

Ibuprofen, and meningitis, 319
IGIV. See *Immunoglobulin, intravenous.*
Immune complexes, after milk ingestion, 441–442
systemic effects, 442–445
Immune response, HIV pathogenesis, 98–100
Immune system activation, in inflammatory bowel disease, 523–527
Immunoactive therapy, clinical trials, 103–104
rationale, 102–103
Immunoblasts, in Guillain-Barré syndrome, 259
Immunodeficiency, common variable, gastrointestinal manifestations, **423–434**
B cells, normal maturation, 423–424
clinical presentation, 425
laboratory evaluation, 425–426
manifestations, 426–432
therapy, 432
intravenous immunoglobulin treatment, **17–28**
X chromosome and, 206–207
See also *Human immunodeficiency virus.*
Immunogenetics, in amyotrophic lateral sclerosis, 332–333
in myasthenia gravis, 285–288
in neurologic disease, **201–212**, 213–214, 216–217
genes involved in, 201–203
HLA antigens and, 204–205
immunoglobulin allotypes, 207
lymphocyte migration, 207
molecular mimicry, 214–216
multiple factors in, 207–209

nonimmunologic effects of immunoreactive substances, 209–210
T-cell recognition, 205–206
X chromosome genes, 206–207
Immunoglobulin A (IgA), antibodies after intravenous immunoglobulin, 23–24
in B-cell differentiation, 161–166
selective deficiency, **435–449**
gastrointestinal diseases, 437–439
immunologic findings, 439–440
cellular mucosal alterations, 440
IgM substitution for IgA, 439–440
macromolecular antigen absorption, 441–445
anti-idiotypes relating to dietary antigen, 444–445
immune complexes, after milk ingestion, 441–442
systemic effects, 442–445
nonimmunologic mucosal abnormalities, 440–441
system, **349–368**
intracellular assembly of, 354–357
selective transport, 355–357
origin, migration, and homing of, 358–361
tissue distribution of IgA1+ and IgA2+ cells, 361
structural aspects, 349–354
alpha chains, 350–352
J chain, 352–353
secretory component, 353–354
T-cell regulation, 362–365
Immunoglobulin deficiency, B cells and antibodies, 138–139
Immunoglobulin E (IgE), of B cells, differentiation pathway, 145–147
and Fc episilon receptors, 148–150
Immunoglobulin G (IgG), in SLE, 324–325
Immunoglobulin M (IgM), monoclonal gammopathy, neuropathy in, 305–306
substitution for IgA, 439–440
Immunoglobulins, allotypes of, 207
in Guillain-Barré syndrome, 260
intravenous (IGIV), in immunoregulatory disorders and in newborns, **39–50**
bullous pemphigoid, 45
hemophilia, 45
idiopathic thrombocytopenic purpura, 40–43
Kawasaki disease, 43–44
myasthenia gravis, 44–45
neutropenia and autoimmune hemolytic anemia, 43
prematures and newborns, 45–46
systemic lupus erythematosus, 45
for infections, treatment and prophylaxis, **29–38**
bacterial, 30–34
in malignancies, 34
neonatal, 32–33
older infants and children, 33–34
viral, 34–36
cytomegalovirus, 34–35
echovirus, 35–36
herpesvirus, 35
respiratory syncytial virus, 36
rotavirus, 36
for post-infection fatigue syndrome, 139
in primary immunodeficiency diseases, **17–28**
efficacy, 19–22
intramuscular, 19–20
intravenous, 20–22
safety, 22–25
antibodies to IgA, 23–24
immunomodulation, 24–25
injection and infusion reactions, 22–23
virus transmission, 24
Immunopathology, virus-induced, 233–234
Immunosuppression, anti–T-cell antibodies, 71–72
Immunotherapy, monoclonal antibodies in, 217–220
Infants and children, bacterial infections, 32–34
IGIV treatment of idiopathic thrombocytopenic purpura, 40–43
premature, IGIV treatment, 45–46
Infection, immunology of, **137–144**
B cells and antibody regulation, 137–139
bacterial, IGIV treatment, 30–34
in malignancies, 34
neonatal, 32–33
in older infants and children, 33–34
HIV, clinical manifestations of, 100–102
T cells and lymphokine regulation, 139–143
viral, IGIV treatment, 34–36
cytomegalovirus, 34–35
echovirus, 35–36
herpesvirus, 35
respiratory syncytial virus, 36
rotavirus, 36
Infectious disease, encephalomyelitis after, **239–240, 242–245**
before Guillain-Barré syndrome, 252–255
neurologic disease after, **239–249**
in SLE, 323–324
viral. See *Viral infections.*
Infectious mononucleosis, preceding Guillain-Barré syndrome, 254
Inflammatory bowel disease, **521–542**
and arthritis, 561–562
cell-mediated, antigen-specific memory events, 527–531
inflammatory and nonspecific effector mechanisms, 531–535
immunopharmacology and mechanisms of drug actions, 536–537

Inflammatory bowel disease *(Continued)*
initiating events and activation of immune system, 523–527
Injection reactions immunoglobulin concentrates, 22–23
Insulinoma, neuropathy with, 306–307
Interferon, neuroendocrine effects of, 191–192
in tuberculosis pleuritis, 141–142
Interferon-gamma, 380
Interleukin-2, therapeutic applications of, 121–130
activated cells, heteroconjugate antibody effects, 126–128
for advanced cancer, 124–126
in melanoma, 121–124
receptor targeting, in delayed-type hypersensitivity, 129–130
toxin, **69–77**
anti-IL-2 receptor antibodies, 70–71
anti-IL-sR monoclonal antibodies in transplantation, 71
genetic construction, 73–74
immunosuppression mediation, 71–72
mechanism of action, 74–75
murine models, 75–77
OKT3 monoclonal antibody, 69–70
rejection, prevention of, 72–73
structure and function, 74
Interleukins, in gastrointestinal immune system function, 379–381
neuroendocrine effects of, 191–192
Intestinal bypass, and arthritis, 561
Isospora belli infections in AIDS, 456

J chains, 352–353
JC virus, in progressive multifocal leukoencephalopathy, 232
JHM virus, immunopathology induced by, 234

Kainic acid, leukocyte effects, 187
Kaposi's sarcoma, intestinal, in AIDS, 460–461
Kawasaki disease, IGIV treatment, 43–44
Keratitis, in herpes simplex virus infection, 230
Killer cells, and Fc epsilon receptors, 149
lymphokine activated, 131–133, 383

Laboratory, clinical immunology, developments in, **113–119**
age effects, 114–116
nutrition, 114
Second Annual Clinical Immunology Society Meeting, 117–118
stress, 116–117
Lamina propria, bacterial infections, 405–408
intestinal, T-cell activation, 377–378
T-cell subpopulations, 371
regulatory function, 374–375
Leu-1 B, human, autoantibody secretion, **1–15**
human, autoantibody secretion, **1–15**
Leukocytes, neuromediator effects, 186–187
neuromediators isolated from, 192–193
Leukoencephalopathy, progressive multifocal, 2320233
Leukoregulin, 160
Limbic encephalitis, with neoplastic disease, 290–300
Liver disease, in AIDS, 463–464
Lung cancer, photoreceptor degeneration with, 309
Lupoid sclerosis, 319
Lupus cerebritis, 320–321
Lupus erythematosus, systemic, 565
antibodies in, 321–323
aseptic meningitis, 319
cerebrospinal fluid analysis, 324–325
cerebrovascular accident, 318
IGIV treatment, 45
migraine, 319–320
movement disorders, 318
and nervous system disease, **315–329**
clinical features, 316–320
diagnosis, 323–325
pathogenesis, 320–323
treatment, 325–326
neuropathy, 317–318
neuropsychiatric problems, drug-induced, 324
non-organic non-psychotic psychopathology, 320
organic mental syndrome, 316–317
pseudotumor cerebri, 320
seizures, 317
transverse myelitis, 318–319
vascular headache, 319–320
Lyme disease, and Guillain-Barré syndrome, 255
Lymph nodes, mesenteric, bacterial infections, 404–407
Lymphocytes, and cell-mediated immunity, **369–389**
cytokines, role of, 379–382
antibody-dependent, 384–386
classification of T-cell subpopulations, 382
interferon-gamma, 381
interleukins, 379–381
lymphotoxin, 381
cytotoxic function, 383–388

cytolytic cells, 388
intraepithelial lymphocytes, 387–388
non-antigen-specific, 384
T-cell cytotoxicity, 386–387
HLA antigen recognition, 214
immunoregulatory function of T cells, 374–377
lymphoid compartments of intestinal immune system, 370
migration of, genetic control, 207
neuroendocrine factors, 388
phenotypic characteristics, 370–374
intraepithelial lymphocytes, 371–373
lamina propria T-cell subpopulations, 371
markers of lymphocyte activation, 373–374
T-cell activation in intestinal lamina propria, 377–379
T-cell antigen-receptor–triggered function, 382–383
tumor-infiltrating, in advanced cancer, 124–126
See also *B cells; T cells.*
Lymphocytic choriomeningitis, 227
Lymphoid cells, staining in graft-versus-host disease, 550–551
Lymphokines, **121–135**
B-cell effects of, in viral infections, 232–233
interleukin-2, biology of, 131–135
therapeutic applications of, 121–130
neuroendocrine effects, 190–192
Lymphoma, amyotrophic lateral sclerosis and, 336–337
intestinal, in AIDS, 461
subacute motor neuropathy, 309–310
Lymphotoxin, 380

Macrophages, neuromediator effects on, 186–187
Major histocompatibility complex, in neurologic disease, 204–205
genetic considerations, 202–203
immune response genes, 213–214
Malignant diseases, bacterial infections, 34
stress effects, 117
Mast cells, and gastrointestinal hypersensitivity, 477–478, 479–480
neuromediator effects, in immediate hypersensitivity, 186
Measles, and encephalomyelitis, 242–245
subacute sclerosing panencephalitis, 230–232
Melanoma, cyclophosphamide and IL-2 treatment, 121–124
Memory events, cell-mediated, antigen-specific, in inflammatory bowel disease, 527–531
Meningitis, aseptic, in SLE, 319
Methylprednisolone, in SLE, 326
Microflora, in graft-versus-host disease, 552
Microsporidia infections in AIDS, 456–457
Migraine, in SLE, 319–320
Milk and food allergies in children, **485–504**
clinical manifestations, 495–497
gastrointestinal tract, 495–496
respiratory tract, 495
skin, 496–497
definition, 485–486
diagnosis, 497–499
dietary eliminations, 497–498
intestinal biopsy, 499
oral challenges, 498
radio-allergosorbent technique, 498–499
serologic tests, 499
skin testing, 498
incidence, 486
mucosal barrier, 486–491
mucosal immune system, 488–491
nonimmune components, 487–488
pathogenesis, 491–495
Type I: immediate-type hypersensitivity, 491–493
Type II: antibody-dependent cytotoxicity, 493
Type III: immune complex–mediated hypersensitivity, 493–494
Type IV: cell-mediated hypersensitivity, 494–495
therapy, 499–500
Milk ingestion, and immune complexes, 441–442
Monoclonal antibodies, in myasthenia gravis, 288–289
Monoclonal gammopathy, amyotrophic lateral sclerosis and, 337–338
neuropathy with, 302–306
Monocytes, endotoxin effects, 142–143
neuromediator effects, 186–187
Monokines, neuroendocrine effects, 190–192
Mononuclear cells, histamine releasing factor, 152–155
Mononucleosis, infectious, and Guillain-Barré syndrome, 254
Motor neuron disorders, monoclonal gammopathy, 337–338
See also *Amyotrophic lateral sclerosis.*
Motor neuropathy, subacute, with lymphoma, 309–310
Movement disorders, in SLE, 318
Mucosal immunity, B-cell differentiation, **161–167**
cellular and molecular events, 161–162
IgA role, 163–166
lymphokines, 162–163
Multiple myeloma, and neuropathy, 302–303
Multiple sclerosis, HLA antigens, 204, 214
immune response genes, 216–217

Myasthenia gravis, **277–293**
experimental, autoimmunity and, 287–200
genetic control, 285–286
immunnoregulation, 287
T cells and, 286–287
treatment, 288–290
human, clinical manifestations, 282–283
diagnosis, 284
HLA antigens, 204, 214–215
immune response genes, 216–217
immunology, 278–282
laboratory evaluation, 283–284
pathogenesis, 277–282
treatment, 284–285
IGIV treatment, 44–45
Mycobacterium avium-intracellulare infections in AIDS, 457
Mycoplasmic infection, preceding Guillain-Barré syndrome, 254–255
Myelin basic protein, in encephalomyelitis, 240, 244–245
Myelinotoxicity, in Guillain-Barré syndrome, 262–263
Myelitis, transverse, in SLE, 318–319
Myeloma, neuropathy in, 303–304
Myelopathy, necrotizing, with neoplastic disease, 300–301
Myoclonus, with neoplastic disease, 301–302

Narcolepsy, genetic influences, 209–210
HLA antigens, 314
Natural killer cells, intestinal lymphocytes, 383
Necrotizing myelopathy, with neoplastic disease, 300–301
Neoplasms, paraneoplastic syndromes and. See *Paraneoplastic syndromes.*
Neuroblastoma, opsoclonus-myoclonus, 301–302
Neuroendocrine factors, and intestinal immune system, 386
Neuroimmune disorders, after vaccination, **239–249**
amyotrophic lateral sclerosis, **331–341**
autoimmunity, **213–221**
genetics, **201–212**
Guillain-Barré syndrome, **251–275**
myasthenia gravis, **277–293**
neuroimmunologic mediators, **183–200**
paraneoplastic syndromes, **295–314**
systemic lupus erythematosus, **315–329**
viral infections, **223–238, 239–249**
Neuroleukin antibodies, in amyotrophic lateral sclerosis, 336
Neuromediators, pathogenetic roles of, **183–200**
in disease development, 194–195
in immediate hypersensitivity, 184–186
in lymphocyte regulation, 188–190
in phagocytic leukocyte functions, 186–187
leukocyte-derived factors, 192–193
lymphokine effects, 190–192
monokine effects, 190–192
receptors for, on lymphocytes, 190
Neuromuscular junction, autoimmune attack on, in myasthenia gravis, 277–282
Neuron-reactive antibodies, in SLE, 321–323
Neuropathy, in amyloidosis, 302, 304–305
in insulinoma, 306–307
in lymphoma, 309–310
in monoclonal gammopathy, 302–306
in SLE, 317–318
in Waldenstrom's macroglobulinemia, 302
Neutralizing epitope, of reovirus type 3, 169–172
Neutropenia, IGIV treatment, 43
Newborns, bacterial infections, 32–33
IGIV treatment, 45–46
Nutrition, and clinical immunology laboratory, 114

OKT3 monoclonal antibodies, 69–70
Opsoclonus-myoclonus, with neoplastic disease, 301–302
Organic mental syndrome, in SLE, 316–317
Osteolytic myeloma, neuropathy in, 303–304
Osteosclerotic myeloma, 304

Paraneoplastic syndrome of nervous system, **295–314**
amyotrophic lateral sclerosis, 336–337
Eaton-Lambert syndrome, 307–309
general features, 296
with IgM monoclonal gammopathy, 305–306
with insulinoma, 306–307
limbic encephalitis, 299–300
with lymphoma, 309–310
monoclonal gammopathy neuropathies, 302–306
with myeloma, 303–304
necrotizing myelopathy, 300–301
opsoclonus-myoclonus, 301–302
photoreceptor degeneration, 309
with primary systemic amyloidosis, 304–305
subacute cerebellar degeneration, 296–298
subacute motor neuropathy, 309–310
subacute sensory neuronopathy, 298–299

Parasites, intestinal, in AIDS, 455–457
Cryptosporidium, 455–456
Isospora belli, 456
Microsporidia, 456–457
See also *Bacterial and parasitic infections.*
Peptide, multiple antigenic (MAP), synthetic vaccines, 172–178
Peptide histidine isoleucine, in immediate hypersensitivity, 184
lymphocyte effects, 189–190
Periarteritis nodosum, 565–566
Peripheral neuropathy, in SLE, 317–318
Phagocytosis, neuromediator effects, 186–187
Photoreceptor degeneration, with neoplastic disease, 309
Plasma cells, in immune response to virus, 225–226
Plasmapheresis, in Guillain-Barré syndrome, 268–271
POEMS syndrome, 304
Polysaccharides, T-cell response to, 139–141
Prednisone, in Guillain-Barré syndrome, 268–269
Premature infants, IGIV treatment, 45–46
Progressive multifocal leukoencephalopathy, 232–233
Protein, fusion, IL-2 toxin, 72
production and assembly, antiretroviral therapy, 85–86
Pseudotumor cerebri, in SLE, 320
Psychiatric disorders in SLE. See *Lupus erythematosus, systemic.*
Psychosis, in SLE, 316–317
from steroid therapy, 324
Pulse therapy, with steroids, in SLE, 326
Purkinje cell antibodies, 297–298
Pyridostigmine, in myasthenia gravis, 285

Rabies vaccine, and encephalomyelitis, 239–242
Radioallergosorbent technique, 498–499
Receptors, T-cell, HLA antigen recognition, 205–206
Reiter's syndrome, 560–561
Rejection, 72–73
fusion protein, 72
IL-2 receptor, 73
intoxication via diphtheria toxin, 73
Reovirus type 3, neutralizing epitope, 169–172
9BG5 antibody, 170–171
T-helper cell domain, 171–172
Respiratory syncytial virus, 36
Respiratory tract, in food allergies, 496
Retrovir, 89–90
Retrovirus, and amyotrophic lateral sclerosis 337
See also *Antiretroviral therapy.*
Ricin antigen, in myasthenia gravis treatment, 290
Rotavirus, 36

Salmonella, infections in AIDS, 462
Salmonella typhi, 408–409
Salmonella typhimurium, 407–408
Schistosomiasis, 411–413
Sciatic nerve testing, in Guillain-Barré syndrome, 265–266
Scleroderma, 568
Secretory component, 353–354
Seizures, in SLE, 317
Semple rabies vaccine, 240–242
Sensory neuronopathy, subacute, with neoplastic disease, 298–299
Shigella, infections in AIDS, 462
in intestinal epithelial cells, 402–404
Sialophorin (CD43), T-cell activation, 61–64
Sjögren's syndrome, 569
Skin testing, for food allergies, 498
Skin, in food allergies, 496–497
SLE. See *Lupus erythematosus, systemic.*
Somatostatin, in immediate hypersensitivity, 184–185
lymphocyte effects, 188–190
Spinal cord, disorders in SLE, 318–319
necrosis of, with neoplastic disease, 300–301
Stress, and clinical immunology laboratory, 116–117
Subacute sensory neuronopathy, 298–299
Substance P, in immediate hypersensitivity, 184–186
leukocyte effects, 187
lymphocyte effects, 188–190
Suppressor T cells, in myasthenia gravis treatment, 298
Systemic lupus erythematosus. See *Lupus erythematosus, systemic.*

T cells, activation, **51–67**
erythrocyte receptor (CD2), 52–59
in intestinal lamina propria, 377–379
LFA-3 binding region, 59–61
sialophorin (CD43), 61–64
antigen-receptor–triggered function of intestinal lymphocytes, 382–383
CD4 differentiation, 378–379
cytotoxic, in measles, 230–232
in viral infections, 226–228
in graft-versus-host disease, 552–553
HLA antigen recognition, 203, 205–206
and IgA responses, 362–365
immature, growth factor, 133–135
lamina propria subpopulations, 371
regulatory function, 374–375

T cells *(Continued)*
and lymphokine regulation, 139–143
in AIDS, 142
bacterial disease, 141
endotoxin effects, 142–143
Epstein-Barr virus effects, 143
interferon production in tuberculosis pleuritis, 141–142
polysaccharide effect, 139–141
in myasthenia gravis, 286–287
Tachykinins, leukocyte effects, 187
Tensilon test, in myasthenia gravis, 283
Theiler's murine encephalomyelitis virus, 233–234
Thrombocytopenic purpura, idiopathic, 40–43
Thymectomy, in myasthenia gravis, 284–285
Thymus dysfunction in graft-versus-host disease, 552
Thyroid disease, amyotrophic lateral sclerosis and, 322–333
Tissue culture studies, in Guillain-Barré syndrome, 261–265
Transplantation, anti-IL-2R monoclonal antibodies, 71
Transverse myelitis, in SLE, 318–319
Tropical spastic paraparesis, 235
Tuberculosis pleuritis, 141–142
Tumor immunology, **157–60**
graft-versus-leukemia reactions, 159–160
leukoregulin actions, 160
Twins, and celiac disease, 512

Uveitis, 117

Vaccination, encephalomyelitis after, **239–242**
in myasthenia gravis treatment, 289–290
Vaccine development, **169–178**
neutralizing epitope of reovirus type 3, 169–172
synthetic peptide vaccines, 172–178
Vasculitis, of central nervous system in SLE, 320–321
Vasoactive intestinal peptide, in immediate hypersensitivity, 184–186
lymphocyte effects of, 188–190
Vasodilators, in immediate hypersensitivity, 185
Vibrio cholerae, 398–400
antipilus and antitoxin immunity, 401–402
cholera toxin immunity, 399–400
enterotoxigenic *Escherichia coli*, 400–402
Viral infections, in AIDS, 457–462
cytomegalovirus, 457–459
diarrhea, idiopathic, 461–462
herpes simplex virus, 459–460
Kaposi's sarcoma, 460–461
lymphoma, 461
amyotrophic lateral sclerosis, 337
of central nervous system, 239–240, 242–245
cytomegalovirus, 34–35
echovirus, 35–36
Epstein-Barr, cellular immune response to, 143
in graft-versus-host disease, 552
and Guillain-Barré syndrome, 253–255
herpesvirus, 35
latency period, and immunity, 229
lifelong immunity after, 232
of nervous system, immune response to, **223–238**
general principles, 224–228
in herpes simplex infection, 228–230
and human immunodeficiency virus, 234–235
humoral vs. cellular, 224, 226–227
immunopathology, 233–234
in progressive multifocal leukoencephalopathy, 232–233
in subacute sclerosing panencephalitis, 230–232
respiratory syncytial virus, 36
rotovirus, 36
See also *HIV*.
Virus neutralization, in immune response, 226
Visna, retrovirus mechanisms, 235

Waldenstrom's macroglobulinemia, with neuropathy, 302
Whipple's disease, 562
Workshops, Clinical Immunology Laboratory, **113–119**
Immediate Hypersensitivity, **145–155**
Immunology of Infection, **137–144**
Lymphokines, **121–135**
Mucosal Immunity, **161–167**
Tumor Immunology, **157–160**
Vaccine Development, **169–178**

X chromosome, and immunodeficiency, 206–207

Yersinia enterocolitica, 406–407